I don't know the cash burn, but I think the management are all workng for shares. I guess this is either confidence (my take) or desperation.
Assuming something good happens with the upcoming trials, the possibilities open up. In the medium term, it seems they are able to make it through to the expected R&D refunds around September noted above.
In the interim, if I have wins elsewhere, I might double down on my options while we are in the orphan period.
Add to My Watchlist
What is My Watchlist?
